generation of inhibitors of PDE type 4, and by selective agonists of subtype A2ARs. Other goals are promising that the Na. 2 Ca Ca 2 and the absorption of the TRP family Target phosphodiesterase type 4 was recognized as a promising approach for the treatment of COPD in the relief of symptoms My CP-690550 slow the progression of the disease, increased Hte strength, which reduces the speed of t exacerbations and improving Lebensqualit Of the urgent need for drugs, embroidered l develop the symptoms reduction in mortality and my t, and the potential for billions of dollars in marketing for the treatment of COPD have pushed RD of PDE4 inhibitors in pipeline development products of large pharmaceutical companies found in recent years.
The first clinical trial data for the second generation PDE4 inhibitors cilomilast and rofl umilast stero not all stressed the successful introduction of a novel Infl ammatory anti serving therapy what doctors in YM155 the fight against severe COPD, but then the progression of cilomilast development slows approvable stage for more than two years, the announcement of the termination of the agreement umilast rofl between Altana and Pfi develop destroy, has concerns about the efficiency increased therapeutic efficiency ht selectively inhibit one or two isoforms of the PDE4 family in the treatment of COPD. 6 months early phase III study RECORD mdr umilast significantly improved lung function and exacerbations fa Significantly reduced compared to placebo cant.
But in the ay YEAR OLD follow-up phase III trials with exacerbations as one of the most important parameters, the results of the study, which included 1513 RATIO europ Ical COPD patients with severe COPD or repeat serious mistakes efficiency already requested the efficiency. Moreover rmed the new test data confident that the PDE4 inhibitor umilast rofl, s efficiency was significantly lower than approved treatments such as salmeterol and tiotropium uticasone fl. The lower than expected long-term effectiveness efficiency of exacerbation therapy umilast rofl community again investigate the RD r Targeting of PDE4 in COPD is one of the gr Th unmet needs in the treatment of the disease is to reduce or eliminate exacerbations. In November 2005, Altana announced the withdrawal of the NDA for europ Ical rofl umilast and opted for clinical trial data for submission of a MAA wait tomorrow.
The hold-up is no doubt that the reduction of RD PDE4 inhibitor promising in the development of COPD. The inhibition of PDE4 and COPD COPD is a complex disease with pathophysiological functions, including normal infl ammation, airway obstruction, airway Gef Redevelopment bronchiolar alveol Re pulmonary hyperinfl tion, pulmonary gas exchange abnormalities and hypertension. Progressive loss of lung function ends leads to reductions in the patients Lebensqualit t and the results of the exacerbations, heart and lungs death. It is gesch protected That chronic non-infectious Se inflammation underlies the pathogenesis and regular progression of the disease Moderately. Pathological changes Ver In patients with COPD is not completely Constantly reversible and it often takes several years for a patient at risk of suffering from the advances in limiting air circulation ow light, moderate, heavy and very heavy C